Collectively, Prasad’s plans would transform the FDA’s decades-old process of approving vaccines by compelling pharmaceutical companies to run far larger studies, probably slowing them down, said current and former agency staff and outside public health experts, some of whom spoke on the condition of anonymity to discuss internal FDA operations or comment on a developing situation.
The approach could also have a chilling effect on the development of novel vaccines, because manufacturers will need to undertake sweeping new studies when seeking most new approvals – even for expanding the population who can get the shot, they said. They also cautioned that the full implications are difficult to understand based on a single email that did not offer a detailed accounting of how the changes would be enacted.
Prasad’s continued questions about the value of administering multiple vaccines at the same time also represent a potential reversal of years of federal guidance. His team’s findings could have implications for vaccines that are placed on the Centres for Disease Control and Prevention’s recommended schedule for childhood vaccines, which calls for administering multiple vaccines at key milestones, such as a child’s birthday. Health officials also encourage Americans to receive multiple vaccines for respiratory illnesses, including flu, Covid and RSV, in the same visit for convenience.
Sign up to Herald Premium Editor’s Picks, delivered straight to your inbox every Friday. Editor-in-Chief Murray Kirkness picks the week’s best features, interviews and investigations. Sign up for Herald Premium here.